These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 2659740

  • 41. [New protocols for myeloma chemotherapy plus IFN alpha].
    Kitani T.
    Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Combination therapy of M2-protocol and interferon-alpha as remission induction in refractory multiple myeloma.
    Shimamoto Y, Matsuzaki M, Ono K, Sano M, Yamaguchi M.
    Haematologia (Budap); 1991 Apr; 24(1):9-11. PubMed ID: 1813363
    [Abstract] [Full Text] [Related]

  • 49. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL, Rahman MJ, Begum M, Dipta TF, Baqui MN, Aziz A, Rahman F, Debnath RC, Habib MA.
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
    Mizuno H, Yamao H, Nagura E, Shimizu K, Kamiya O, Takeyama H, Nitta M, Wakita A, Ichikawa A, Kobayashi M, Kawashima K, Saito H, Nagoya Myeloma Cooperative Study Group.
    Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
    [Abstract] [Full Text] [Related]

  • 52. Marked and sustained improvement of systemic sclerosis following polychemotherapy for coexistent multiple myeloma.
    Bachleitner-Hofmann T, Machold K, Knobler R, Drach J, Grumbeck E, Gisslinger H.
    Clin Exp Rheumatol; 2002 Apr; 20(1):85-8. PubMed ID: 11892717
    [Abstract] [Full Text] [Related]

  • 53. [Therapy of multiple myeloma and its complications].
    Avvisati G, Pulsoni A, Petrucci MT, Tribalto M.
    Recenti Prog Med; 1990 Oct; 81(10):642-50. PubMed ID: 2291008
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Erythropoietin in multiple myeloma].
    Pecherstorfer M, Schmoranzer F, Vesely M, Fortelny A, Baumgartner G.
    Dtsch Med Wochenschr; 1990 Jul 13; 115(28-29):1096-9. PubMed ID: 2373040
    [Abstract] [Full Text] [Related]

  • 56. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma.
    Sakalová A, Bock PR, Dedík L, Hanisch J, Schiess W, Gazová S, Chabronová I, Holomanova D, Mistrík M, Hrubisko M.
    Cancer Chemother Pharmacol; 2001 Jul 13; 47 Suppl():S38-44. PubMed ID: 11561871
    [Abstract] [Full Text] [Related]

  • 57. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S, Saslavsky J, Tezanos Pinto M, Palmer L, Curuchet M, Lein JM, Garay G, Dragosky M, Quiroga-Micheo E, Huberman AB.
    J Clin Oncol; 1984 Jul 13; 2(7):836-40. PubMed ID: 6376722
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.